Triple inhalers for obstructive airways disease: will they be useful?

References

• Nannini L, Cates C, Lasserson T et al. Combined corticosteroid and long-acting β-agonist in one inhaler versus long-acting β-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.4, CD006829 (2007).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.356, 775–789 (2007).
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.21, 74–81 (2003).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Kuna P, Monso E et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir. Med.104, 1858–1868 (2010).
   PubMed Web of Science ®Google Scholar
• Yang IA, Fong KM, Sim EH et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2, CD002991 (2007).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration80, 89–95 (2010).
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Vandemheen KL et al. Methodological issues in therapeutic trials of COPD. Eur. Respir. J.31, 927–933 (2008).
   PubMed Web of Science ®Google Scholar
• Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J.34, 13–16 (2009).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of COPD – 2006 Update. Am. J. Respir. Crit. Care Med.176, 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA300, 2407–2416 (2008).
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med.123, 1001–1006 (2010).
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis.5, 189–195 (2010).
   PubMedGoogle Scholar
• Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.359, 1543–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet374, 1171–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med.177, 19–26 (2008).
   PubMed Web of Science ®Google Scholar
• Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting β2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.3, CD007891 (2010).
   Google Scholar
• Singh D, Brooks J, Hagan G et al. Superiority of ‘triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax63, 592–598 (2008).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ando F, Santus P et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther.20, 556–561 (2007).
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med.146, 545–555 (2007).
   PubMed Web of Science ®Google Scholar
• Karner C, Cates CJ. Combination inhaled steroid and long-acting β(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.3, CD008532 (2011).
   Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J.34, 757–769 (2009).
   PubMed Web of Science ®Google Scholar
• Korn S, Kerwin E, Atis S et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir. Med.105(5), 719–726 (2011).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pocock SJ, Magnussen H et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther.23, 165–171 (2010).
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Ramos-Barbon D, Jack D et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir. Res.11, 135 (2010).
   PubMed Web of Science ®Google Scholar
• Chapman KR, Rennard SI, Dogra A et al. Long-term Safety and Efficacy of Indacaterol, a Novel Long-acting {β}2-Agonist, in Subjects with COPD: a Randomized, Placebo-controlled Study. Chest DOI: 10.1378/chest.10-1830 (2011) (Epub ahead of print).
   Google Scholar
• van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest129, 509–517 (2006).
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir. Med.104, 995–1004 (2010).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Pearle J, Iezzoni D et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD6, 17–25 (2009).
   PubMedGoogle Scholar
• Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr. Opin. Investig. Drugs10, 482–490 (2009).
   PubMed Web of Science ®Google Scholar
• Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J. Allergy Clin. Immunol.119, 344–350 (2007).
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni CM, Greenstone I et al. Addition of long-acting β2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst. Rev.5, CD005535 (2010).
   PubMed Web of Science ®Google Scholar
• Edwards SJ, von Maltzahn R, Naya IP et al. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int. J. Clin. Pract.64, 619–627 (2010).
   PubMed Web of Science ®Google Scholar
• Magnussen H, Bugnas B, van Noord J et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir. Med.102, 50–56 (2008).
   PubMed Web of Science ®Google Scholar
• Park HW, Yang MS, Park CS et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy64, 778–783 (2009).
   PubMed Web of Science ®Google Scholar
• Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet364, 1505–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med.363, 1715–1726 (2010).
   PubMed Web of Science ®Google Scholar
• Lavorini F, Magnan A, Christophe DJ et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med.102, 593–604 (2007).
   PubMed Web of Science ®Google Scholar
• Pitchayajittipong C, Shur J, Price R. Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid. Pharm. Res.26, 2657–2666 (2009).
   PubMed Web of Science ®Google Scholar
• Ray NC, Alcaraz L. Muscarinic antagonist-β-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin. Ther. Pat.19, 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Emerging pharmacotherapies for COPD. Chest134, 1278–1286 (2008).
   PubMed Web of Science ®Google Scholar